$APVO
Aptevo Therapeutics Inc. Stock $apvo

$apvo Overview Financials Valuation SEC Filings Company Website

2021 Q3 Form 10-Q Financial Statement

#000156459021056494 Filed on November 12, 2021

Income Statement

Concept	2021 Q3	2020 Q3	2020 Q2
Revenue	$3.096M	$1.460M	$473.0K
YoY Change	112.05%	-83.8%	-93.57%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.479M	$3.220M	$2.840M
YoY Change	8.04%	-50.28%	-56.56%
% of Gross Profit
Research & Development	$4.367M	$4.490M	$4.440M
YoY Change	-2.74%	-50.79%	-42.58%
% of Gross Profit
Depreciation & Amortization	$296.0K	$300.0K	$300.0K
YoY Change	-1.33%	-44.44%	-48.28%
% of Gross Profit
Operating Expenses	$7.846M	$7.710M	$7.280M
YoY Change	1.76%	-50.58%	-30.03%
Operating Profit	-$4.750M		-$6.807M
YoY Change			-47.22%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$2.327M	-$700.0K	$4.000K
YoY Change	232.43%	11.11%	-100.92%
Pretax Income	-$7.077M	-$6.950M	-$6.800M
YoY Change	1.83%	-37.8%	-37.27%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$6.997M	-$6.791M	-$6.803M
YoY Change	3.03%	-1.86%	-48.96%
Net Earnings / Revenue	-226.0%	-465.14%	-1438.27%
Basic Earnings Per Share	-$1.43
Diluted Earnings Per Share	-$1.430M	-$2.102M	-$2.105M
COMMON SHARES
Basic Shares Outstanding	4.892M
Diluted Shares Outstanding	4.892M

Balance Sheet

Concept	2021 Q3	2020 Q3	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$52.12M	$24.90M	$7.600M
YoY Change	109.31%	40.68%	-63.81%
Cash & Equivalents	$53.38M	$27.50M	$10.15M
Short-Term Investments
Other Short-Term Assets	$3.659M	$4.300M	$2.600M
YoY Change	-14.91%	188.4%	-17.98%
Inventory
Prepaid Expenses
Receivables	$3.096M	$1.500M	$300.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$58.87M	$30.70M	$10.50M
YoY Change	91.77%	-16.55%	-75.96%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.386M	$6.000M	$6.600M
YoY Change	-26.9%	40.48%	43.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$746.0K	$800.0K	$757.0K
YoY Change	-6.75%	-76.39%	-39.34%
Total Long-Term Assets	$5.132M	$6.700M	$8.009M
YoY Change	-23.4%	-71.81%	-64.29%
TOTAL ASSETS
Total Short-Term Assets	$58.87M	$30.70M	$10.50M
Total Long-Term Assets	$5.132M	$6.700M	$8.009M
Total Assets	$64.00M	$37.40M	$18.51M
YoY Change	71.14%	-38.24%	-72.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.687M	$3.900M	$4.662M
YoY Change	-5.46%	-67.7%	-60.84%
Accrued Expenses	$3.104M	$2.600M	$2.000M
YoY Change	19.38%	-40.91%	-44.44%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%
Long-Term Debt Due	$11.17M	$0.00	$0.00
YoY Change
Total Short-Term Liabilities	$32.38M	$7.400M	$7.000M
YoY Change	337.57%	-80.14%	-57.83%
LONG-TERM LIABILITIES
Long-Term Debt	$4.012M	$25.20M	$0.00
YoY Change	-84.08%		-100.0%
Other Long-Term Liabilities	$20.32M	$2.600M	$2.900M
YoY Change	681.58%	21566.67%	22207.69%
Total Long-Term Liabilities	$24.33M	$27.80M	$2.900M
YoY Change	-12.47%	231566.67%	-85.18%
TOTAL LIABILITIES
Total Short-Term Liabilities	$32.38M	$7.400M	$7.000M
Total Long-Term Liabilities	$24.33M	$27.80M	$2.900M
Total Liabilities	$56.71M	$35.20M	$9.900M
YoY Change	61.12%	-13.75%	-75.21%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$7.292M	$2.202M	$8.650M
YoY Change
Total Liabilities & Shareholders Equity	$64.00M	$37.40M	$18.50M
YoY Change	71.14%	-38.24%	-72.02%

Cashflow Statement

Concept	2021 Q3	2020 Q3	2020 Q2
OPERATING ACTIVITIES
Net Income	-$6.997M	-$6.791M	-$6.803M
YoY Change	3.03%	-1.86%	-48.96%
Depreciation, Depletion And Amortization	$296.0K	$300.0K	$300.0K
YoY Change	-1.33%	-44.44%	-48.28%
Cash From Operating Activities	-$5.242M	-$7.390M	-$4.630M
YoY Change	-29.07%	-1.99%	-70.88%
INVESTING ACTIVITIES
Capital Expenditures	-$13.00K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$13.00K	$0.00	$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-3.021M	24.73M	0.000
YoY Change	-112.22%	123550.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-5.242M	-7.390M	-4.630M
Cash From Investing Activities	-13.00K	0.000	0.000
Cash From Financing Activities	-3.021M	24.73M	0.000
Net Change In Cash	-8.276M	17.34M	-4.630M
YoY Change	-147.73%	-630.28%	-71.08%
FREE CASH FLOW
Cash From Operating Activities	-$5.242M	-$7.390M	-$4.630M
Capital Expenditures	-$13.00K	$0.00
Free Cash Flow	-$5.229M	-$7.390M
YoY Change	-29.24%	-1.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	we effected a 1-for-14 reverse stock split (the “Reverse Split”) of our common stock pursuant to which every 14 shares of our common stock issued and outstanding as of March 26, 2020 were automatically combined into one issued and outstanding share of common stock. No fractional shares were issued as a result of the reverse stock split.
CY2020Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.071
CY2020Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.071
CY2019Q1	apvo	Pre Funded Warrants And Rights Outstanding Term PreFundedWarrantsAndRightsOutstandingTerm	P10Y
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-7.35
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0.14
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	4.04
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.80
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.31
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2824000
	apvo	Increase Decrease In Long Term Operating Lease Liability IncreaseDecreaseInLongTermOperatingLeaseLiability	750000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4617357
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3233257
	us-gaap	Profit Loss ProfitLoss	-22185000
	us-gaap	Profit Loss ProfitLoss	-10697000
	us-gaap	Share Based Compensation ShareBasedCompensation	1465000
	us-gaap	Share Based Compensation ShareBasedCompensation	1057000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	884000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1064000
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-4000
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	14338000
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2104000
	apvo	Non Cash Interest Expense And Other NonCashInterestExpenseAndOther	4387000
	apvo	Non Cash Interest Expense And Other NonCashInterestExpenseAndOther	606000
	apvo	Increase Decrease In Royalties Receivable IncreaseDecreaseInRoyaltiesReceivable	727000
	apvo	Increase Decrease In Royalties Receivable IncreaseDecreaseInRoyaltiesReceivable	1463000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	39000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	455000
	apvo	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	857000
	apvo	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	757000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1695000
	apvo	Increase Decrease In Long Term Operating Lease Liability IncreaseDecreaseInLongTermOperatingLeaseLiability	725000
	apvo	Increase Decrease In Assets And Liabilities Held For Sale IncreaseDecreaseInAssetsAndLiabilitiesHeldForSale	-1719000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17799000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23195000
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	28120000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	595000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-595000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	28120000
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	24730000
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	10550000
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	22104000
	apvo	Repayments Under Liability Related To Sale Of Future Royalties RepaymentsUnderLiabilityRelatedToSaleOfFutureRoyalties	5531000
	apvo	Proceeds From Sale Of Future Royalties ProceedsFromSaleOfFutureRoyalties	35000000
	apvo	Transaction Costs From Sale Of Future Royalties TransactionCostsFromSaleOfFutureRoyalties	1100000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	200000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	985000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10233000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29237000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2626000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	10843000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7551000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	19946000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	53377000
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27497000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	16594000
CY2021Q1	apvo	Proceeds From Exercise Of Stock Options Value ProceedsFromExerciseOfStockOptionsValue	-86000
CY2021Q1	apvo	Proceeds From Exercise Of Warrants Value ProceedsFromExerciseOfWarrantsValue	-506000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-7256000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	10504000
CY2021Q2	apvo	Proceeds From Exercise Of Stock Options Value ProceedsFromExerciseOfStockOptionsValue	-25000
CY2021Q2	apvo	Proceeds From Exercise Of Warrants Value ProceedsFromExerciseOfWarrantsValue	-478000
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10234000
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1600000
	apvo	Operating Lease Property Number Of Copiers OperatingLeasePropertyNumberOfCopiers	4
	apvo	Finance Lease Number Of Equipment FinanceLeaseNumberOfEquipment	1
	us-gaap	Operating Lease Cost OperatingLeaseCost	1185000
CY2020Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	395000
CY2021Q3	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	2000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-7932000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	13881000
CY2020Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-6948000
CY2021Q3	apvo	Proceeds From Exercise Of Stock Options Value ProceedsFromExerciseOfStockOptionsValue	-89000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	11842000
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	413000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	2897000
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	15152000
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	301000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-6803000
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	8650000
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	343000
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-6791000
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	2202000
CY2020Q1	apvo	Fractional Shares Reverse Stock Split FractionalSharesReverseStockSplit	0
	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent liabilities in the unaudited condensed consolidated financial statements and accompanying notes. Estimates are used for, but not limited to, forecasted royalties, effective interest rates, clinical accruals, useful lives of equipment, commitments and contingencies, and stock-based compensation forfeiture rates. Given the global economic climate and additional or unforeseen effects from the ongoing COVID-19 pandemic, these estimates are becoming more challenging, and actual results could differ materially from those estimates.</p>
CY2021Q1	apvo	Proceeds From Sale Of Investments ProceedsFromSaleOfInvestments	35000000
CY2021Q1	apvo	Payment Of Royalty Purchase Agreement Percentage PaymentOfRoyaltyPurchaseAgreementPercentage	1.90
CY2021Q1	apvo	Payment Of Royalty Interest Percentage PaymentOfRoyaltyInterestPercentage	0.50
CY2020Q1	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	14300000
	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	-1580000
	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	14338000
	apvo	Milestone Payment MilestonePayment	227000
CY2021Q3	apvo	Disposal Group Including Discontinued Operations Deferred Revenue DisposalGroupIncludingDiscontinuedOperationsDeferredRevenue	80000
CY2020Q3	apvo	Disposal Group Including Discontinued Operations Deferred Revenue DisposalGroupIncludingDiscontinuedOperationsDeferredRevenue	157000
	apvo	Disposal Group Including Discontinued Operations Deferred Revenue DisposalGroupIncludingDiscontinuedOperationsDeferredRevenue	399000
	apvo	Disposal Group Including Discontinued Operations Deferred Revenue DisposalGroupIncludingDiscontinuedOperationsDeferredRevenue	297000
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	80000
CY2020Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	157000
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	626000
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	13055000
CY2021Q3	apvo	Disposal Group Including Discontinued Operations Deferred Revenue DisposalGroupIncludingDiscontinuedOperationsDeferredRevenue	100000
CY2021Q3	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0
CY2020Q3	us-gaap	Adjustment For Amortization AdjustmentForAmortization	100000
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	100000
	apvo	Depreciation Or Capital Expenditures DepreciationOrCapitalExpenditures	0
CY2021Q3	apvo	Depreciation Or Capital Expenditures DepreciationOrCapitalExpenditures	0
CY2020Q3	apvo	Depreciation Or Capital Expenditures DepreciationOrCapitalExpenditures	0
	apvo	Depreciation Or Capital Expenditures DepreciationOrCapitalExpenditures	0
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	14300000
	apvo	Investing Non Cash Items InvestingNonCashItems	0
	apvo	Investing Non Cash Items InvestingNonCashItems	0
	apvo	Increase Decrease In Research And Development Expense IncreaseDecreaseInResearchAndDevelopmentExpense	100000
	apvo	Increase Decrease In Research And Development Expense IncreaseDecreaseInResearchAndDevelopmentExpense	100000
CY2021Q3	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	47900000
CY2020Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	35400000
CY2021Q3	us-gaap	Cash Cash	4218000
CY2020Q4	us-gaap	Cash Cash	4601000
CY2021Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	47900000
CY2020Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	35378000
CY2021Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	1259000
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	2555000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53377000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42534000
CY2020Q3	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	25000000.0
CY2021Q1	apvo	Payment Of Amount Outstanding PaymentOfAmountOutstanding	10000000.0
CY2021Q1	apvo	Proceeds From Sale Of Investments ProceedsFromSaleOfInvestments	35000000.0
CY2021Q1	apvo	Payment Of Royalty Purchase Agreement Percentage PaymentOfRoyaltyPurchaseAgreementPercentage	1.90
CY2021Q1	apvo	Payment Of Royalty Interest Percentage PaymentOfRoyaltyInterestPercentage	0.50
CY2021Q2	apvo	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	33349000
CY2021Q3	apvo	Non Cash Interest Expense NonCashInterestExpense	1841000
CY2021Q3	us-gaap	Payments For Royalties PaymentsForRoyalties	3110000
CY2021Q3	apvo	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	32080000
CY2021Q3	apvo	Liability Related To Sale Of Future Royalties Current LiabilityRelatedToSaleOfFutureRoyaltiesCurrent	-13369000
CY2021Q3	apvo	Liability Related To Sale Of Future Royalties Non Current LiabilityRelatedToSaleOfFutureRoyaltiesNonCurrent	18711000
	apvo	Operating Lease Property Number Of Lab Equipment OperatingLeasePropertyNumberOfLabEquipment	1
CY2021Q3	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	395000
	us-gaap	Operating Lease Cost OperatingLeaseCost	1185000
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	5000
CY2020Q3	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	2000
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	5000
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000
CY2021Q3	us-gaap	Lease Cost LeaseCost	397000
	us-gaap	Lease Cost LeaseCost	1190000
CY2020Q3	us-gaap	Lease Cost LeaseCost	397000
	us-gaap	Lease Cost LeaseCost	1191000
CY2021Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-1.45
CY2020Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-2.15
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-4.94
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-7.35
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0.02
CY2020Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0.05
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1865000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2722000
	us-gaap	Operating Lease Payments OperatingLeasePayments	1053000
	us-gaap	Operating Lease Payments OperatingLeasePayments	1134000
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y7M6D
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1446
CY2020Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y6M
CY2020Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1453
CY2021Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-7077000
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-22811000
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-23752000
CY2021Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	80000
CY2020Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	157000
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	626000
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	13055000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-6997000
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-6791000
	us-gaap	Net Income Loss NetIncomeLoss	-22185000
	us-gaap	Net Income Loss NetIncomeLoss	-10697000
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0.14
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	4.04
CY2021Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.43
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.10
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.80
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.31
CY2021Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4891881
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3232811
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4617357
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3233257
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10200000
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	24.8
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	319000
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	343000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1464000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1057000
CY2019Q1	apvo	Prefunded Warrant Expiration Date PrefundedWarrantExpirationDate	2029-03-11

Files In Submission

Name	View Source	Status
0001564590-21-056494-index-headers.html	Edgar Link	pending
0001564590-21-056494-index.html	Edgar Link	pending
0001564590-21-056494.txt	Edgar Link	pending
0001564590-21-056494-xbrl.zip	Edgar Link	pending
apvo-10q_20210930.htm	Edgar Link	pending
apvo-10q_20210930_htm.xml	Edgar Link	completed
apvo-20210930.xsd	Edgar Link	pending
apvo-20210930_cal.xml	Edgar Link	unprocessable
apvo-20210930_def.xml	Edgar Link	unprocessable
apvo-20210930_lab.xml	Edgar Link	unprocessable
apvo-20210930_pre.xml	Edgar Link	unprocessable
apvo-ex103_46.htm	Edgar Link	pending
apvo-ex104_47.htm	Edgar Link	pending
apvo-ex311_9.htm	Edgar Link	pending
apvo-ex312_7.htm	Edgar Link	pending
apvo-ex321_6.htm	Edgar Link	pending
apvo-ex322_8.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g5b3glclkp0c000001.jpg	Edgar Link	pending
g5b3glclkp0c000002.jpg	Edgar Link	pending
g5b3glclkp0c000003.jpg	Edgar Link	pending
ga1cawysiklp000001.jpg	Edgar Link	pending
ga1cawysiklp000002.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$APVO
Aptevo Therapeutics Inc. Stock $apvo

2021 Q3 Form 10-Q Financial Statement

#000156459021056494 Filed on November 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APVO Aptevo Therapeutics Inc. Stock $apvo

2021 Q3 Form 10-Q Financial Statement

#000156459021056494 Filed on November 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APVO
Aptevo Therapeutics Inc. Stock $apvo